{ "schemaVersion": 1, "organisationId": "O-ae8182a5a37f46b38bab106c82235e25", "slug": "envista-holdings-corp", "name": "Envista Holdings Corp", "updatedAt": "2026-10-02T13:50:12.180145Z", "sections": [ { "type": "OVERVIEW", "text": "Envista Holdings Corp. is a global dental-products company whose technologies, equipment, consumables, and services support dental professionals in diagnosing, treating, and helping prevent conditions affecting teeth, gums, and supporting bone, as well as dental aesthetics. Its two core businesses are Specialty Products & Technologies, including implants, orthodontic products, prosthetics, and related technologies, and Equipment & Consumables, including imaging, dental-office equipment, restorative products, and infection-prevention solutions. [P83253759][P26677938][P56750454]\n\nEnvista serves dental professionals in more than 130 countries, with company facilities in over 30 countries. It reported FY2025 sales of approximately $2.72 billion, and its corporate website describes a worldwide workforce of more than 12,000 employees. The company states its purpose as “to partner with professionals to improve lives.” Envista became an independent company in 2019 after separating from Danaher. [P16730410][https://envistaco.com/en/about-us][https://investors.envistaco.com/2019-12-18-Envista-Completes-Separation-From-Danaher]\n[P83253759][P26677938][P56750454][P16730410][https://envistaco.com/en/about-us][https://investors.envistaco.com/2019-12-18-Envista-Completes-Separation-From-Danaher]", "updatedAt": "2026-10-02T13:50:12.180145Z" }, { "type": "PRODUCTS", "text": "Envista’s implant and restoration products include Nobel Biocare, Alpha-Bio Tec, Implant Direct and NobelProcera. The portfolio covers implant systems, guided surgery, biomaterials and regenerative solutions, as well as prefabricated and custom prosthetics for single-tooth through full-mouth restorations. The company also provides implant-related clinical education and treatment-planning software. [P49032926][P107649436]\n\nIts orthodontic products include Ormco bracket systems, the Damon bracket-and-wire system and Spark clear aligners. Spark is designed for mild-to-complex malocclusion and uses TruGEN and TruGEN XR materials; its Approver software supports treatment planning and customization, and the workflow integrates with intraoral scanners. Imaging and digital products include DEXIS and i-CAT X-ray, panoramic and 3D imaging systems, intraoral scanners and 2D X-ray sensors. DTX Studio software brings together imaging, scans and clinical photographs and supports diagnosis, implant planning and 2D/3D workflows with AI tools. [P26677938][P38494385][P21943371][P70999399][P5875431]\n\nOther offerings include Kerr restorative and endodontic products—such as cements, bonding agents, root-canal products, curing lights and impression materials—and Metrex infection-prevention products, including CaviWipes and CaviCide disinfectants. The portfolio also includes visualization and magnification systems, loupes, services and spare parts. [P30572448][P56750454]\n\nIn FY2025, Specialty Products & Technologies represented approximately 64% of Envista’s $2.72 billion in sales, and Equipment & Consumables approximately 36%. Consumables, services and spare parts accounted for 93% of Specialty Products & Technologies sales and about 70% of Equipment & Consumables sales; individual product or brand revenue shares were not reported. [P26677938][P56750454][T6566362]\n[P49032926][P107649436][P26677938][P38494385][P21943371][P70999399][P5875431][P30572448][P56750454][T6566362][T6566362][T6566362]", "updatedAt": "2026-10-02T13:50:12.180145Z" }, { "type": "GEOGRAPHY", "text": "In 2025, Envista generated $2.72 billion in sales. The United States accounted for $1.28 billion (about 47%); China, $194 million (about 7%); and all other countries combined, $1.24 billion (about 46%). No individual country outside the United States and China represented 5% or more of sales. By market grouping, 2025 sales were 51% North America, 23% Western Europe, 22% emerging markets and 4% other developed markets; 53% of sales were outside the United States. Emerging markets include Eastern Europe, the Middle East, Africa, Latin America and Asia excluding Japan and Australia. [P58548883][P67407160]\n\nAt year-end 2025, Envista reported approximately 32 significant office, research and development, manufacturing and distribution facilities: 12 in five U.S. states and 20 in 13 other countries, primarily in Europe, with additional presence in Asia, the rest of North America, Latin America and the Middle East. Its products and services are available worldwide, and it serves dental professionals in more than 130 countries. [T8308255][P228704]\n\nEnvista had approximately 12,000 employees at year-end 2025: about 3,000 in the United States and 9,000 outside it. The filing does not provide a more detailed employee breakdown by country or region. Its careers site describes a North American presence of 10+ locations and approximately 4,000 employees, and 30+ offices and manufacturing facilities across Europe and the Middle East; that website information is not dated and is not directly comparable with the year-end 2025 employee figures. [P20484430][P66133151][https://careers.envistaco.com/locations]\n[P58548883][P67407160][T8308255][P228704][P20484430][P66133151][https://careers.envistaco.com/locations]", "updatedAt": "2026-10-02T13:50:12.180145Z" }, { "type": "SEGMENTS", "text": "Envista reports two business segments. **Specialty Products & Technologies** includes dental implant systems and regenerative solutions, dental prosthetics and related software and technologies, orthodontic brackets and aligners, laboratory products, and loupes. In FY2025, it generated $1,752.8 million in sales, approximately 64.5% of Envista’s $2,719.5 million total. [P26677938][T10276803]\n\n**Equipment & Consumables** includes dental-office equipment, digital imaging and software, visualization and magnification systems, endodontic products, restorative materials and instruments, and infection-prevention products. FY2025 sales were $966.7 million, approximately 35.5% of total sales. [P56750454][T10276803] In the six months ended July 3, 2026, the two segments contributed approximately 64.7% and 35.3% of sales, respectively. [T16836524]\n[P26677938][T10276803][P56750454][T16836524]", "updatedAt": "2026-10-02T13:50:12.180145Z" }, { "type": "HISTORY", "text": "Envista’s roots predate its formation as a company: Danaher assembled parts of its dental portfolio through acquisitions including KaVo in 2004, Sybron Dental Specialties in 2006, and Nobel Biocare in 2014. The eventual portfolio also included equipment businesses built through acquisitions of Gendex in 2004 and PaloDEx in 2009. [P67777006][https://investors.danaher.com/2004-05-28-Danaher-Corporation-Announces-Completion-of-the-Kaltenbach-Voigt-GmbH-Co-KG-KaVo-Acquisition-and-the-Telecom-Tools-Test-Sets-and-Test-Systems-Product-Lines-Acquisition-From-Harris-Corporation][https://investors.danaher.com/2006-05-19-Danaher-Successfully-Completes-Acquisition-of-Sybron-Dental-Specialties-Inc][https://investors.danaher.com/2014-09-14-Danaher-to-Acquire-Nobel-Biocare-Holding-AG-for-CHF-17-10-per-share] Danaher announced its plan to spin off its dental segment in June 2018, and Envista was formed that year as a wholly owned subsidiary. It was named Envista Holdings Corporation in 2019, began trading on the New York Stock Exchange on September 18, 2019, and completed its separation from Danaher on December 18, 2019. [P58325538][https://investors.envistaco.com/2018-06-19-Danaher-Announces-Plan-To-Spin-Off-Dental-Business-Into-An-Independent-Publicly-Traded-Company][https://investors.envistaco.com/2019-06-23Danaher-Announces-New-Dental-Company-To-Be-Named-Envista-Holdings-Corporation][https://investors.envistaco.com/2019-09-20-Envista-Announces-IPO-Closing][https://investors.envistaco.com/2019-12-18-Envista-Completes-Separation-From-Danaher]\n\nIn 2020, orthodontics brand Ormco announced the U.S. launch of its Spark clear aligner system. Envista reshaped its portfolio in 2021–22, selling KaVo’s treatment-unit and instrument business to Planmeca while retaining its imaging business, and acquiring Carestream Dental’s intraoral-scanner business, which became part of the DEXIS brand. [https://www.prnewswire.com/news-releases/america-meet-spark-the-new-clearer-more-comfortable-doctor-directed-aligner-treatment-301185419.html][https://investors.envistaco.com/2021-09-07-Envista-Announces-Intended-Sale-Of-KaVo-Treatment-Unit-Instrument-Business-To-Planmeca][https://investors.envistaco.com/2022-01-03-Envista-Closes-Divestiture-of-KaVo-Treatment-Unit-Instrument-Business][https://investors.envistaco.com/2021-12-22-ENVISTA-TO-ACQUIRE-CARESTREAM-DENTAL-INTRA-ORAL-SCANNER-BUSINESS][https://investors.envistaco.com/2022-04-20-Envista-Completes-Acquisition-of-Carestream-Dentals-Intraoral-Scanner-Business] In 2024, Paul Keel was appointed CEO effective May 1, succeeding Amir Aghdaei. [https://investors.envistaco.com/2024-02-26-Envista-Holdings-Announces-Planned-CEO-Succession-Process][https://investors.envistaco.com/2024-04-15-Envista-Announces-CEO-Appointment]\n[P67777006][P58325538][https://investors.danaher.com/2004-05-28-Danaher-Corporation-Announces-Completion-of-the-Kaltenbach-Voigt-GmbH-Co-KG-KaVo-Acquisition-and-the-Telecom-Tools-Test-Sets-and-Test-Systems-Product-Lines-Acquisition-From-Harris-Corporation][https://investors.danaher.com/2006-05-19-Danaher-Successfully-Completes-Acquisition-of-Sybron-Dental-Specialties-Inc][https://investors.danaher.com/2014-09-14-Danaher-to-Acquire-Nobel-Biocare-Holding-AG-for-CHF-17-10-per-share][https://investors.envistaco.com/2018-06-19-Danaher-Announces-Plan-To-Spin-Off-Dental-Business-Into-An-Independent-Publicly-Traded-Company][https://investors.envistaco.com/2019-06-23Danaher-Announces-New-Dental-Company-To-Be-Named-Envista-Holdings-Corporation][https://investors.envistaco.com/2019-09-20-Envista-Announces-IPO-Closing][https://investors.envistaco.com/2019-12-18-Envista-Completes-Separation-From-Danaher][https://www.prnewswire.com/news-releases/america-meet-spark-the-new-clearer-more-comfortable-doctor-directed-aligner-treatment-301185419.html][https://investors.envistaco.com/2021-09-07-Envista-Announces-Intended-Sale-Of-KaVo-Treatment-Unit-Instrument-Business-To-Planmeca][https://investors.envistaco.com/2022-01-03-Envista-Closes-Divestiture-of-KaVo-Treatment-Unit-Instrument-Business][https://investors.envistaco.com/2021-12-22-ENVISTA-TO-ACQUIRE-CARESTREAM-DENTAL-INTRA-ORAL-SCANNER-BUSINESS][https://investors.envistaco.com/2022-04-20-Envista-Completes-Acquisition-of-Carestream-Dentals-Intraoral-Scanner-Business][https://investors.envistaco.com/2024-02-26-Envista-Holdings-Announces-Planned-CEO-Succession-Process][https://investors.envistaco.com/2024-04-15-Envista-Announces-CEO-Appointment]", "updatedAt": "2026-10-02T13:50:12.180145Z" } ], "sources": [ { "id": "P83253759", "href": "https://app.finbar.com/go?id=P83253759", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P26677938", "href": "https://app.finbar.com/go?id=P26677938", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P56750454", "href": "https://app.finbar.com/go?id=P56750454", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P16730410", "href": "https://app.finbar.com/go?id=P16730410", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "https://envistaco.com/en/about-us", "href": "https://envistaco.com/en/about-us", "label": "envistaco.com" }, { "id": "https://investors.envistaco.com/2019-12-18-Envista-Completes-Separation-From-Danaher", "href": "https://investors.envistaco.com/2019-12-18-Envista-Completes-Separation-From-Danaher", "label": "investors.envistaco.com" }, { "id": "P49032926", "href": "https://app.finbar.com/go?id=P49032926", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P107649436", "href": "https://app.finbar.com/go?id=P107649436", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P38494385", "href": "https://app.finbar.com/go?id=P38494385", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P21943371", "href": "https://app.finbar.com/go?id=P21943371", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P70999399", "href": "https://app.finbar.com/go?id=P70999399", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P5875431", "href": "https://app.finbar.com/go?id=P5875431", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P30572448", "href": "https://app.finbar.com/go?id=P30572448", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "T6566362", "href": "https://app.finbar.com/go?id=T6566362", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P58548883", "href": "https://app.finbar.com/go?id=P58548883", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P67407160", "href": "https://app.finbar.com/go?id=P67407160", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "T8308255", "href": "https://app.finbar.com/go?id=T8308255", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P228704", "href": "https://app.finbar.com/go?id=P228704", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P20484430", "href": "https://app.finbar.com/go?id=P20484430", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "P66133151", "href": "https://app.finbar.com/go?id=P66133151", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "https://careers.envistaco.com/locations", "href": "https://careers.envistaco.com/locations", "label": "careers.envistaco.com" }, { "id": "T10276803", "href": "https://app.finbar.com/go?id=T10276803", "label": "Envista Holdings Corp — Full financial report (2025 Y)", "documentId": "D-83862a7648e2414c8f9e8b2b66a8b091" }, { "id": "T16836524", "href": "https://app.finbar.com/go?id=T16836524", "label": "Envista Holdings Corp — Full financial report (2026 Q 2)", "documentId": "D-52f2ffdb7fc346f7b784979fceb3b42b" }, { "id": "P67777006", "href": "https://app.finbar.com/go?id=P67777006", "label": "Envista Holdings Corp — Full financial report (2019 Y)", "documentId": "D-1b2dd47d2d014c9ca76d78d2867acd33" }, { "id": "https://investors.danaher.com/2004-05-28-Danaher-Corporation-Announces-Completion-of-the-Kaltenbach-Voigt-GmbH-Co-KG-KaVo-Acquisition-and-the-Telecom-Tools-Test-Sets-and-Test-Systems-Product-Lines-Acquisition-From-Harris-Corporation", "href": "https://investors.danaher.com/2004-05-28-Danaher-Corporation-Announces-Completion-of-the-Kaltenbach-Voigt-GmbH-Co-KG-KaVo-Acquisition-and-the-Telecom-Tools-Test-Sets-and-Test-Systems-Product-Lines-Acquisition-From-Harris-Corporation", "label": "investors.danaher.com" }, { "id": "https://investors.danaher.com/2006-05-19-Danaher-Successfully-Completes-Acquisition-of-Sybron-Dental-Specialties-Inc", "href": "https://investors.danaher.com/2006-05-19-Danaher-Successfully-Completes-Acquisition-of-Sybron-Dental-Specialties-Inc", "label": "investors.danaher.com" }, { "id": "https://investors.danaher.com/2014-09-14-Danaher-to-Acquire-Nobel-Biocare-Holding-AG-for-CHF-17-10-per-share", "href": "https://investors.danaher.com/2014-09-14-Danaher-to-Acquire-Nobel-Biocare-Holding-AG-for-CHF-17-10-per-share", "label": "investors.danaher.com" }, { "id": "P58325538", "href": "https://app.finbar.com/go?id=P58325538", "label": "Envista Holdings Corp — Full financial report (2019 Y)", "documentId": "D-1b2dd47d2d014c9ca76d78d2867acd33" }, { "id": "https://investors.envistaco.com/2018-06-19-Danaher-Announces-Plan-To-Spin-Off-Dental-Business-Into-An-Independent-Publicly-Traded-Company", "href": "https://investors.envistaco.com/2018-06-19-Danaher-Announces-Plan-To-Spin-Off-Dental-Business-Into-An-Independent-Publicly-Traded-Company", "label": "investors.envistaco.com" }, { "id": "https://investors.envistaco.com/2019-06-23Danaher-Announces-New-Dental-Company-To-Be-Named-Envista-Holdings-Corporation", "href": "https://investors.envistaco.com/2019-06-23Danaher-Announces-New-Dental-Company-To-Be-Named-Envista-Holdings-Corporation", "label": "investors.envistaco.com" }, { "id": "https://investors.envistaco.com/2019-09-20-Envista-Announces-IPO-Closing", "href": "https://investors.envistaco.com/2019-09-20-Envista-Announces-IPO-Closing", "label": "investors.envistaco.com" }, { "id": "https://www.prnewswire.com/news-releases/america-meet-spark-the-new-clearer-more-comfortable-doctor-directed-aligner-treatment-301185419.html", "href": "https://www.prnewswire.com/news-releases/america-meet-spark-the-new-clearer-more-comfortable-doctor-directed-aligner-treatment-301185419.html", "label": "www.prnewswire.com" }, { "id": "https://investors.envistaco.com/2021-09-07-Envista-Announces-Intended-Sale-Of-KaVo-Treatment-Unit-Instrument-Business-To-Planmeca", "href": "https://investors.envistaco.com/2021-09-07-Envista-Announces-Intended-Sale-Of-KaVo-Treatment-Unit-Instrument-Business-To-Planmeca", "label": "investors.envistaco.com" }, { "id": "https://investors.envistaco.com/2022-01-03-Envista-Closes-Divestiture-of-KaVo-Treatment-Unit-Instrument-Business", "href": "https://investors.envistaco.com/2022-01-03-Envista-Closes-Divestiture-of-KaVo-Treatment-Unit-Instrument-Business", "label": "investors.envistaco.com" }, { "id": "https://investors.envistaco.com/2021-12-22-ENVISTA-TO-ACQUIRE-CARESTREAM-DENTAL-INTRA-ORAL-SCANNER-BUSINESS", "href": "https://investors.envistaco.com/2021-12-22-ENVISTA-TO-ACQUIRE-CARESTREAM-DENTAL-INTRA-ORAL-SCANNER-BUSINESS", "label": "investors.envistaco.com" }, { "id": "https://investors.envistaco.com/2022-04-20-Envista-Completes-Acquisition-of-Carestream-Dentals-Intraoral-Scanner-Business", "href": "https://investors.envistaco.com/2022-04-20-Envista-Completes-Acquisition-of-Carestream-Dentals-Intraoral-Scanner-Business", "label": "investors.envistaco.com" }, { "id": "https://investors.envistaco.com/2024-02-26-Envista-Holdings-Announces-Planned-CEO-Succession-Process", "href": "https://investors.envistaco.com/2024-02-26-Envista-Holdings-Announces-Planned-CEO-Succession-Process", "label": "investors.envistaco.com" }, { "id": "https://investors.envistaco.com/2024-04-15-Envista-Announces-CEO-Appointment", "href": "https://investors.envistaco.com/2024-04-15-Envista-Announces-CEO-Appointment", "label": "investors.envistaco.com" } ] }